Table 3.
Summary of efficacy data
| mCRC cohort | Non-CRC cohort | All patients | |
|---|---|---|---|
| n = 32 | n = 7 | n = 39 | |
| Best overall response within 24 weeks, n (%) | |||
| Complete response (CR) | 0 (0) | 1 (14) | 1 (3) |
| Partial response (PR) (unconfirmed) | 5 (16) | 5 (71) | 10 (26) |
| Partial response (PR) (confirmed) | 5 (16) | 2 (29) | 7 (18) |
| Stable disease (SD) | 10 (32) | 2 (29) | 12 (32) |
| Progressive disease (PD) | 11 (35) | 0 (0) | 11 (29) |
| Not evaluated according to RECIST | 1 | 0 | 1 |
| Confirmed ORR, n (%) | 5 (16) | 3 (43) | 8 (21) |
| Clinical benefit rate at 24 weeks (CR+PR+SD) | 20 (65) | 7 (100) | 27 (73) |
| Best overall metabolic response at 4 weeks, n (%) | |||
| CMR | 1 (4) | 0 (0) | 1 (3) |
| PMR | 16 (62) | 4 (67) | 20 (54) |
| SMD | 0 (0) | 1 (17) | 1 (3) |
| PMD | 9 (35) | 1 (17) | 10 (31) |
| Not evaluateda | 6 | 1 | 7 |
| Median PFS (months) | 3.9 | 5.5 | 4.2 |
Abbreviation: ORR, overall response rate.
aPatients not assessed by FDG-PET at week 4.